ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Worldwide Local Anesthesia Drugs Industry to 2026 - Bupivacaine is Expected to Register Significant Growth - ResearchAndMarkets.com

September 29, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Sep 29, 2021--

The “Local Anesthesia Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)” report has been added to ResearchAndMarkets.com’s offering.

The global local anesthesia drugs market was valued at USD 2,526.86 million in 2020, and it is expected to reach USD 3,378.43 million by 2026, registering a CAGR of 4.91% during the forecast period.

Companies Mentioned

  • Baxter International Inc.
  • Fresenius SE & Co. KGaA
  • Glenmark Pharmaceutical Inc.
  • Mylan N.V.
  • Pacira Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Septodont
  • Teva Pharmaceutical Industries Ltd

ADVERTISEMENT

Key Market Trends

Bupivacaine is Expected to Register a Significant Growth in the Forecast Years

Bupivacaine is a prescription medication used as a local anesthetic that blocks the nerve impulses that send pain signals to the brain. This injection is a very useful anesthetic for local and regional anesthesia for several procedures, such as surgery and diagnostic, therapeutic, and obstetrical procedures. It is used in various surgical procedures.

Although all local anesthetics cause changes in the cardiac and central nervous system functions, in the case of Bupivacaine, when injected intravascularly into toxic blood concentrations, it can cause an atrioventricular block, ventricular arrhythmias, and cardiac arrest, sometimes resulting in death.

Pacira Pharmaceuticals Inc. is one of the growing companies recognized for its drug Exparel globally. LGM Pharma, Pfizer, Sagent Pharmaceuticals Inc., and BOC Sciences are the key players globally. In March 2021, the US Food and Drug Administration (FDA) approved the submission of supplemental new drug application (sNDA) submitted by Pacira BioSciences Inc. for the expanded use of its Exparel (Bupivacaine Liposome Injectable Suspension) in pediatric patients. However, Bupivacaine is widely used as local anesthesia due to its efficacy in numbing certain organs. Hence, the rising number of surgeries leads to the high demand for local anesthesia drugs, and it is expected to propel the growth of the market.

North America Dominates the Market and is Expected to Follow the Same Trend Over the Forecast Period

ADVERTISEMENT

North America currently dominates the local anesthesia drugs market and is expected to continue its stronghold in the market. The North American anesthesia market is the largest regional market in the world. The market is mainly driven by factors, such as the increasing number of surgeries, the rising aging population with increasing chronic conditions, and advancements in anesthesia technologies.

For instance, according to the American Society of Plastic Surgeons (ASPS), in 2020, about 2,314,720 cosmetic surgical procedures were performed in the United States, as compared to 1,901,049 procedures in 2000. There has been a 22% increase in the adoption rate of these surgical procedures, within a decade. These statistics clearly indicate that surgical procedures are constantly increasing in the region.

As per the Canadian Institute for Health Information (CIHI), around 104,349 Caesarean section deliveries, 70,215 knee replacement surgeries, 55,294 fracture rectifications, 42,449 coronary artery angioplasties, and 58,333 hip replacement surgeries were performed in the country during 2017-2018. These statistics indicate that the demand for local anesthesia is expected to be high in the near future

In addition, several companies are focusing on new product launches and seeking product approvals in Canada. For instance, in December 2019, Heron Therapeutics Inc., a commercial-stage biotechnology company, was granted a review status and accepted by Health Canada for its new drug submission (NDS) for HTX-011, an investigational dual-acting, fixed-dose combination of the local anesthetic called Bupivacaine, along with a low dose of the nonsteroidal anti-inflammatory drug, Meloxicam, for the management of post-operative pain.

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Number of Surgeries

4.2.2 New Approval of Anesthetic Drugs

4.2.3 Growing Use of Local Anesthetic in Post-operative Pain

4.3 Market Restraints

4.3.1 Side Effects of Anesthetic Drugs

4.3.2 Regulatory Framework

4.4 Porter’s Five Forces Analysis

5 MARKET SEGMENTATION

5.1 By Drug Type

5.2 By Mode of Administration

5.3 Geography

6 COMPETITIVE LANDSCAPE

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/wx4zjt

View source version on businesswire.com:https://www.businesswire.com/news/home/20210929005610/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 09/29/2021 09:53 AM/DISC: 09/29/2021 09:53 AM

http://www.businesswire.com/news/home/20210929005610/en